Rani Therapeutics Holdings, Inc. (RANI)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Rani Therapeutics Holdings, Inc. (RANI) is a publicly traded company in the Healthcare sector. Latest price: $0.59. Market cap $38.54M. Trailing PE -2.19. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Valuation
| P/E (TTM) | -2.19× |
|---|---|
| P/S (TTM) | 7.90× |
| P/B | 2.81× |
| P/FCF (TTM) | -1.89× |
| EV / EBITDA | -1.16× |
| EV / Sales | 7.63× |
| Earnings Yield | -27.29% |
| Free Cash Flow Yield | -52.78% |
Fundamentals
| Enterprise Value | $37.22M |
|---|---|
| Revenue (TTM) | $4.88M |
| Net Income (TTM) | -$10.52M |
| Free Cash Flow (TTM) | -$19.17M |
| Net Debt | -$1.32M |
| Working Capital | $45.88M |
| Gross Margin | 96.70% |
| Operating Margin | -675.80% |
| Net Margin | -618.02% |
| Return on Equity | -129.93% |
| Return on Invested Capital | -63.96% |
Peers
Recent News
- Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
- Rani Therapeutics to Participate in the Chardan Healthcare Conference
- Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
- Rani Therapeutics to Participate in Upcoming September Conferences
- Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
Related
Browse more tickers: sitemap